Gallium-68 DOTATOC for Management of Neuroendocrine Tumors

Status No longer available

Clinical Trial Summary

Gallium-68 DOTATOC is a material used to find neuroendocrine tumors (NETs) using positron emission tomography (PET scan). The material has already been shown to be better than the currently available imaging agents. This study is designed to evaluate the clinical impact of PET CT scanning using this agent in the evaluation and management of patients with NETs.

Clinical Trial Description

Patients with NETs will be evaluated by their own physicians. Before doing the PET scan using Gallium-68 DOTATOC, the physicians will be asked to describe the type of treatment that they would recommend. After the test is performed and the result reviewed, the physician will be asked to reevaluate the therapeutic and management options. Data will be analyzed to determine the impact of the testing on patient management.

Gallium-68 has been designated an "orphan drug" due to the relative rarity of NETs. It is expected that the data collected from this and other similar trials will be used to provide data to the FDA regarding the safety and efficacy of this drug as an imaging agent for NETs and ultimately lead to FDA approval. ;

Study Design

N/A

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02375464
Study type	Expanded Access
Source	Northwell Health
Contact
Status	No longer available
Phase	Phase 3
Start date	April 2015
Completion date	December 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01218555` - Study of Everolimus (RAD001) in Combination With Lenalidomide	Phase 1
Recruiting	`NCT03412877` - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer	Phase 2
Withdrawn	`NCT04614766` - A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors	Phase 1/Phase 2
Recruiting	`NCT05556473` - F-Tryptophan PET/CT in Human Cancers	Phase 1
Completed	`NCT03273712` - Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)	Phase 2
Recruiting	`NCT05636618` - Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors	Phase 1/Phase 2
Terminated	`NCT03986593` - Cryoablation of Bone Metastases From Endocrine Tumors	N/A
Recruiting	`NCT04584008` - Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics	N/A
Completed	`NCT02815969` - The Indol Profile; Exploring the Metabolic Profile of Neuroendocrine Tumors
Completed	`NCT02441062` - Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors	Phase 2
Active, not recruiting	`NCT02174549` - Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer	Phase 1/Phase 2
Completed	`NCT02134639` - PET-CT Imaging of Neuro-endocrine Tumors and Preliminary Clinical Evaluation	N/A
Completed	`NCT02132468` - A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers	Phase 2
Recruiting	`NCT01201096` - Neo-adjuvant Peptide Receptor Mediated Radiotherapy With 177Lutetium in Front of Curative Intended Liver Transplantation in Patients With Hepatic Metastasis of Neuroendocrine Tumors (NEO-LEBE)	N/A
Terminated	`NCT01163526` - Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies	N/A
Completed	`NCT01099228` - Combination Targeted Radiotherapy in Neuroendocrine Tumors	N/A
Completed	`NCT00171873` - Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut	Phase 3
Active, not recruiting	`NCT05077384` - Open-label Study of Surufatinib in Japanese Patients	Phase 1/Phase 2
Active, not recruiting	`NCT04544098` - Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver	Early Phase 1
Active, not recruiting	`NCT02736500` - Peptide Receptor Radionuclide Therapy With 177Lu-Dotatate Associated With Metronomic Capecitabine In Patients Affected By Aggressive Gastro-Etero-Pancreatic Neuroendocrine Tumors	Phase 1/Phase 2